AbCellera Biologics Inc.
ABCL
$2.37
-$0.02-0.84%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 28.83M | 32.96M | 33.06M | 35.79M | 38.03M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.83M | 32.96M | 33.06M | 35.79M | 38.03M |
| Cost of Revenue | 167.26M | 169.81M | 166.75M | 162.30M | 175.66M |
| Gross Profit | -138.43M | -136.84M | -133.70M | -126.51M | -137.63M |
| SG&A Expenses | 85.49M | 85.40M | 80.96M | 76.99M | 75.18M |
| Depreciation & Amortization | 58.85M | 85.82M | 54.64M | 23.73M | 24.40M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 311.60M | 341.03M | 302.35M | 263.01M | 275.23M |
| Operating Income | -282.77M | -308.06M | -269.29M | -227.23M | -237.21M |
| Income Before Tax | -200.40M | -202.17M | -178.81M | -168.63M | -174.03M |
| Income Tax Expenses | -37.54M | -26.37M | -25.51M | -21.73M | -27.63M |
| Earnings from Continuing Operations | -162.86 | -175.80 | -153.30 | -146.90 | -146.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -162.86M | -175.80M | -153.30M | -146.90M | -146.40M |
| EBIT | -282.77M | -308.06M | -269.29M | -227.23M | -237.21M |
| EBITDA | -189.77M | -222.24M | -214.65M | -203.50M | -212.81M |
| EPS Basic | -0.55 | -0.60 | -0.53 | -0.51 | -0.51 |
| Normalized Basic EPS | -0.43 | -0.49 | -0.41 | -0.39 | -0.39 |
| EPS Diluted | -0.56 | -0.61 | -0.54 | -0.52 | -0.52 |
| Normalized Diluted EPS | -0.43 | -0.49 | -0.41 | -0.39 | -0.39 |
| Average Basic Shares Outstanding | 1.18B | 1.17B | 1.17B | 1.16B | 1.16B |
| Average Diluted Shares Outstanding | 1.18B | 1.17B | 1.17B | 1.16B | 1.16B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
